Translating depression biomarkers for improved targeted therapies

Neuroscience and Biobehavioral Reviews

Volumn 59, Issue , 2015, Pages 1-15

  Bredt, David S ^a   Furey, Maura L ^a   Chen, Guang ^a   Lovenberg, Tim ^a   Drevets, Wayne C ^b   Manji, Husseini K ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

Biomarker; Bipolar; Depression; Glutamate; Imaging; Mood; Neuropharmacology; Synaptic plasticity

Indexed keywords

ABT 436; ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; DOPAMINE RECEPTOR; HYDROCORTISONE; INSULIN RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MIBAMPATOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NELIVAPTAN; RAPASTINEL; TRAXOPRODIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADDICTION; ALZHEIMER DISEASE; ANXIETY DISORDER; BIPOLAR DEPRESSION; BOLD SIGNAL; BRAIN FUNCTION; BRAIN RADIOGRAPHY; BRAIN REGION; CONNECTOME; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; EEG ABNORMALITY; FORCED SWIM TEST; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; HERITABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RESTING STATE NETWORK; RESTLESSNESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP WAKING CYCLE; TAIL SUSPENSION TEST; TRANSLATIONAL RESEARCH; ANIMAL; DEPRESSIVE DISORDER; DRUG EFFECTS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOMARKERS; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; NEURONAL PLASTICITY;

EID: 84944891888     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.09.013     Document Type: Review

References (163)

1. Abdallah C.G., Sanacora G., Duman R.S., Krystal J.H. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 2014, 66:509-523.
2. Aguilera G., Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept. 2000, 96:23-29.
3. Alivisatos A.P., Andrews A.M., Boyden E.S., Chun M., Church G.M., Deisseroth K., Donoghue J.P., Fraser S.E., Lippincott-Schwartz J., Looger L.L., Masmanidis S., McEuen P.L., Nurmikko A.V., Park H., Peterka D.S., Reid C., Roukes M.L., Scherer A., Schnitzer M., Sejnowski T.J., Shepard K.L., Tsao D., Turrigiano G., Weiss P.S., Xu C., Yuste R., Zhuang X. Nanotools for neuroscience and brain activity mapping. ACS Nano 2013, 7:1850-1866.
4. Armstrong T., Olatunji B.O. Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis. Clin. Psychol. Rev. 2012, 32:704-723.
5. Augustinavicius J.L., Zanjani A., Zakzanis K.K., Shapiro C.M. Polysomnographic features of early-onset depression: a meta-analysis. J. Affect. Disord. 2014, 158:11-18.
6. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20:7871-7879.
7. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol. Psychiatry 2008, 64:863-870.
8. Banasr M., Valentine G.W., Li X.Y., Gourley S.L., Taylor J.R., Duman R.S. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol. Psychiatry 2007, 62:496-504.
9. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 2004, 29:185-193.
10. Baskaran A., Milev R., McIntyre R.S. The neurobiology of the EEG biomarker as a predictor of treatment response in depression. Neuropharmacology 2012, 63:507-513.
11. Bellingrath S., Rohleder N., Kudielka B.M. Effort-reward-imbalance in healthy teachers is associated with higher LPS-stimulated production and lower glucocorticoid sensitivity of interleukin-6 in vitro. Biol. Psychol. 2013, 92:403-409.
12. Benedetti F., Barbini B., Bernasconi A., Fulgosi M.C., Campori E., Colombo C., Dallaspezia S., Lorenzi C., Pontiggia A., Radaelli D., Smeraldi E. Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. J. Clin. Psychopharmacol. 2008, 28:249-251.
13. Bernard R., Kerman I.A., Thompson R.C., Jones E.G., Bunney W.E., Barchas J.D., Schatzberg A.F., Myers R.M., Akil H., Watson S.J. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2011, 16:634-646.
14. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 2008, 165:617-620.
15. Blasey C.M., Block T.S., Belanoff J.K., Roe R.L. Efficacy and safety of mifepristone for the treatment of psychotic depression. J. Clin. Psychopharmacol. 2011, 31:436-440.
16. Bleickardt C.J., Mullins D.E., Macsweeney C.P., Werner B.J., Pond A.J., Guzzi M.F., Martin F.D., Varty G.B., Hodgson R.A. Characterization of the V1a antagonist. JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology (Berl.) 2009, 202:711-718.
17. Bogdanova O.V., Kanekar S., D'Anci K.E., Renshaw P.F. Factors influencing behavior in the forced swim test. Physiol. Behav. 2013, 118:227-239.
18. Borsboom D., Cramer A.O. Network analysis: an integrative approach to the structure of psychopathology. Ann. Rev. Clin. Psychol. 2013, 9:91-121.
19. Branchi I. The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology 2011, 36:339-351.
20. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
21. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
22. Chaki S., Ago Y., Palucha-Paniewiera A., Matrisciano F., Pilc A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013, 66:40-52.
23. Chappell A.S., Gonzales C., Williams J., Witte M.M., Mohs R.C., Sperling R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007, 68:1008-1012.
24. Chaudhury D., Walsh J.J., Friedman A.K., Juarez B., Ku S.M., Koo J.W., Ferguson D., Tsai H.C., Pomeranz L., Christoffel D.J., Nectow A.R., Ekstrand M., Domingos A., Mazei-Robison M.S., Mouzon E., Lobo M.K., Neve R.L., Friedman J.M., Russo S.J., Deisseroth K., Nestler E.J., Han M.H. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013, 493:532-536.
25. Chen A.C., Oathes D.J., Chang C., Bradley T., Zhou Z.W., Williams L.M., Glover G.H., Deisseroth K., Etkin A. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19944-19949.
26. Chen C.H., Ridler K., Suckling J., Williams S., Fu C.H., Merlo-Pich E., Bullmore E. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol. Psychiatry 2007, 62:407-414.
27. Chen G., Henter I.D., Manji H.K. Translational research in bipolar disorder: emerging insights from genetically based models. Mol. Psychiatry 2010, 15:883-895.
28. Chen S., Zhou R., Cui H., Chen X. Deficits in cue detection underlie event-based prospective memory impairment in major depression: an eye tracking study. Psychiatry Res. 2013, 209:453-458.
29. Chiuccariello L., Houle S., Miler L., Cooke R.G., Rusjan P.M., Rajkowska G., Levitan R.D., Kish S.J., Kolla N.J., Ou X., Wilson A.A., Meyer J.H. Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. Neuropsychopharmacology 2014, 39:973-980.
30. Cho J.H., Gregersen P.K. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 2011, 365:1612-1623.
31. CONVERGE consortium Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 2015, 523:588-591.
32. Cornwell B.R., Salvadore G., Furey M., Marquardt C.A., Brutsche N.E., Grillon C., Zarate C.A. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 2012, 72:555-561.
33. Covington H.E., Lobo M.K., Maze I., Vialou V., Hyman J.M., Zaman S., LaPlant Q., Mouzon E., Ghose S., Tamminga C.A., Neve R.L., Deisseroth K., Nestler E.J. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 2010, 30:16082-16090.
34. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 2005, 4:775-790.
35. Cunha L., Horvath I., Ferreira S., Lemos J., Costa P., Vieira D., Veres D.S., Szigeti K., Summavielle T., Mathe D., Metello L.F. Preclinical imaging: an essential ally in modern biosciences. Mol. Diagn. Ther. 2014, 18:153-173.
36. Delgado P.L. How antidepressants help depression: mechanisms of action and clinical response. J. Clin. Psychiatry 2004, 65(4 (Suppl.)):25-30.
37. Dichter G.S., Damiano C.A., Allen J.A. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J. Neurodev. Disord. 2012, 4:19.
38. Dorn L.D., Burgess E.S., Friedman T.C., Dubbert B., Gold P.W., Chrousos G.P. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 1997, 82:912-919.
39. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 2010, 67:432-438.
40. Drevets W.C., Savitz J., Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008, 13:663-681.
41. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
42. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
43. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
44. Duncan W.C., Sarasso S., Ferrarelli F., Selter J., Riedner B.A., Hejazi N.S., Yuan P., Brutsche N., Manji H.K., Tononi G., Zarate C.A. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 2013, 16:301-311.
45. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
46. Egeland M., Zunszain P.A., Pariante C.M. Molecular mechanisms in the regulation of adult neurogenesis during stress. Nat. Rev. Neurosci. 2015, 16:189-200.
47. Eisenberger N.I., Inagaki T.K., Mashal N.M., Irwin M.R. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav. Immun. 2010, 24:558-563.
48. Elliott R., Rubinsztein J.S., Sahakian B.J., Dolan R.J. The neural basis of mood-congruent processing biases in depression. Arch. Gen. Psychiatry 2002, 59:597-604.
49. Esser S.K., Hill S.L., Tononi G. Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves. Sleep 2007, 30:1617-1630.
50. Etkin A., Egner T., Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn. Sci. 2011, 15:85-93.
51. Fabio K.M., Guillon C.D., Lu S.F., Heindel N.D., Brownstein M.J., Lacey C.J., Garippa C., Simon N.G. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J. Pharm. Sci. 2013, 102:2033-2043.
52. Faraguna U., Vyazovskiy V.V., Nelson A.B., Tononi G., Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J. Neurosci. 2008, 28:4088-4095.
53. Foland-Ross L.C., Gotlib I.H. Cognitive and neural aspects of information processing in major depressive disorder: an integrative perspective. Front. Psychol. 2012, 3:489.
54. Fournier J.C., Keener M.T., Almeida J., Kronhaus D.M., Phillips M.L. Amygdala and whole-brain activity to emotional faces distinguishes major depressive disorder and bipolar disorder. Bipolar Disord. 2013, 15:741-752.
55. Francis T.C., Chandra R., Friend D.M., Finkel E., Dayrit G., Miranda J., Brooks J.M., Iniguez S.D., O'Donnell P., Kravitz A., Lobo M.K. Nucleus accumbens medium spiny neuron subtypes mediate depression-related outcomes to social defeat stress. Biol. Psychiatry 2014, 77:212-222.
56. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:566-580.
57. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 2006, 63:1121-1129.
58. Furey M.L., Drevets W.C., Hoffman E.M., Frankel E., Speer A.M., Zarate C.A. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry 2013, 70:280-290.
59. Furey M.L., Nugent A.C., Speer A.M., Luckenbaugh D.A., Hoffman E.M., Frankel E., Drevets W.C., Zarate C.A. Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res. 2012, 196:62-67.
60. Garber J., Clarke G.N., Weersing V.R., Beardslee W.R., Brent D.A., Gladstone T.R., DeBar L.L., Lynch F.L., D'Angelo E., Hollon S.D., Shamseddeen W., Iyengar S. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA 2009, 301:2215-2224.
61. Godlewska B.R., Norbury R., Selvaraj S., Cowen P.J., Harmer C.J. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol. Med. 2012, 42:2609-2617.
62. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 2002, 7:254-275.
63. Gould T.D., O'Donnell K.C., Dow E.R., Du J., Chen G., Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008, 54:577-587.
64. Griebel G., Beeske S., Stahl S.M. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry 2012, 73:1403-1411.
65. Grimm S., Ernst J., Boesiger P., Schuepbach D., Hell D., Boeker H., Northoff G. Increased self-focus in major depressive disorder is related to neural abnormalities in subcortical-cortical midline structures. Hum. Brain Mapp. 2009, 30:2617-2627.
66. Guintivano J., Brown T., Newcomer A., Jones M., Cox O., Maher B.S., Eaton W.W., Payne J.L., Wilcox H.C., Kaminsky Z.A. Identification and replication of a combined epigenetic and genetic biomarker predicting suicide and suicidal behaviors. Am. J. Psychiatry 2014, 171:1287-1296.
67. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
68. Harmer C.J. Serotonin and emotional processing: does it help explain antidepressant drug action?. Neuropharmacology 2008, 55:1023-1028.
69. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414.
70. Harrison N.A., Doeller C.F., Voon V., Burgess N., Critchley H.D. Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism. Biol. Psychiatry 2014, 76:585-593.
71. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
72. Hasler G., Fromm S., Carlson P.J., Luckenbaugh D.A., Waldeck T., Geraci M., Roiser J.P., Neumeister A., Meyers N., Charney D.S., Drevets W.C. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch. Gen. Psychiatry 2008, 65:521-531.
73. Hasler G., Luckenbaugh D.A., Snow J., Meyers N., Waldeck T., Geraci M., Roiser J., Knutson B., Charney D.S., Drevets W.C. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol. Psychiatry 2009, 66:201-205.
74. Hodes G.E., Pfau M.L., Leboeuf M., Golden S.A., Christoffel D.J., Bregman D., Rebusi N., Heshmati M., Aleyasin H., Warren B.L., Lebonte B., Horn S., Lapidus K.A., Stelzhammer V., Wong E.H., Bahn S., Krishnan V., Bolanos-Guzman C.A., Murrough J.W., Merad M., Russo S.J. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:16136-16141.
75. Huber T.J., Issa K., Schik G., Wolf O.T. The cortisol awakening response is blunted in psychotherapy inpatients suffering from depression. Psychoneuroendocrinology 2006, 31:900-904.
76. Ibrahim L., Diaz Granados N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., Potter W.Z., Zarate C.A. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 2012, 32:551-557.
77. International Schizophrenia C., Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
78. Jang S.W., Liu X., Yepes M., Shepherd K.R., Miller G.W., Liu Y., Wilson W.D., Xiao G., Blanchi B., Sun Y.E., Ye K. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2687-2692.
79. Kaddurah-Daouk R., Boyle S.H., Matson W., Sharma S., Matson S., Zhu H., Bogdanov M.B., Churchill E., Krishnan R.R., Rush A.J., Pickering E., Delnomdedieu M. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 2011, 1:e26.
80. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 2011, 68:444-454.
81. Keedwell P.A., Drapier D., Surguladze S., Giampietro V., Brammer M., Phillips M. Subgenual cingulate and visual cortex responses to sad faces predict clinical outcome during antidepressant treatment for depression. J. Affect. Disord. 2010, 120:120-125.
82. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 1997, 74:299-316.
83. Kern S., Oakes T.R., Stone C.K., McAuliff E.M., Kirschbaum C., Davidson R.J. Glucose metabolic changes in the prefrontal cortex are associated with HPA axis response to a psychosocial stressor. Psychoneuroendocrinology 2008, 33:517-529.
84. Koike H., Iijima M., Chaki S. Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol. Biochem. Behav. 2013, 107:20-23.
85. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:751-756.
86. Krishnan V., Han M.H., Graham D.L., Berton O., Renthal W., Russo S.J., Laplant Q., Graham A., Lutter M., Lagace D.C., Ghose S., Reister R., Tannous P., Green T.A., Neve R.L., Chakravarty S., Kumar A., Eisch A.J., Self D.W., Lee F.S., Tamminga C.A., Cooper D.C., Gershenfeld H.K., Nestler E.J. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
87. Laje G., Lally N., Mathews D., Brutsche N., Chemerinski A., Akula N., Kelmendi B., Simen A., McMahon F.J., Sanacora G., Zarate C. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry 2012, 72:e27-e28.
88. Leuchter A.F., Cook I.A., Marangell L.B., Gilmer W.S., Burgoyne K.S., Howland R.H., Trivedi M.H., Zisook S., Jain R., McCracken J.T., Fava M., Iosifescu D., Greenwald S. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res. 2009, 169:124-131.
89. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
90. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., Li X.Y., Aghajanian G., Duman R.S. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
91. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330:613-622.
92. Liu Q., Lim P., Singh J., Lewin D., Schwab B., Kent J. Doubly randomized delayed-start design for enrichment studies with responders or nonresponders. J. Biopharm. Stat. 2012, 22:737-757.
93. Liu R.J., Aghajanian G.K. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:359-364.
94. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71:996-1005.
95. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
96. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
97. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S., Wray N.R., Lewis C.M., Hamilton S.P., Weissman M.M., Breen G., Byrne E.M., Blackwood D.H., Boomsma D.I., Cichon S., Heath A.C., Holsboer F., Lucae S., Madden P.A., Martin N.G., McGuffin P., Muglia P., Noethen M.M., Penninx B.P., Pergadia M.L., Potash J.B., Rietschel M., Lin D., Muller-Myhsok B., Shi J., Steinberg S., Grabe H.J., Lichtenstein P., Magnusson P., Perlis R.H., Preisig M., Smoller J.W., Stefansson K., Uher R., Kutalik Z., Tansey K.E., Teumer A., Viktorin A., Barnes M.R., Bettecken T., Binder E.B., Breuer R., Castro V.M., Churchill S.E., Coryell W.H., Craddock N., Craig I.W., Czamara D., De Geus E.J., Degenhardt F., Farmer A.E., Fava M., Frank J., Gainer V.S., Gallagher P.J., Gordon S.D., Goryachev S., Gross M., Guipponi M., Henders A.K., Herms S., Hickie I.B., Hoefels S., Hoogendijk W., Hottenga J.J., Iosifescu D.V., Ising M., Jones I., Jones L., Jung-Ying T., Knowles J.A., Kohane I.S., Kohli M.A., Korszun A., Landen M., Lawson W.B., Lewis G., Macintyre D., Maier W., Mattheisen M., McGrath P.J., McIntosh A., McLean A., Middeldorp C.M., Middleton L., Montgomery G.M., Murphy S.N., Nauck M., Nolen W.A., Nyholt D.R., O'Donovan M., Oskarsson H., Pedersen N., Scheftner W.A., Schulz A., Schulze T.G., Shyn S.I., Sigurdsson E., Slager S.L., Smit J.H., Stefansson H., Steffens M., Thorgeirsson T., Tozzi F., Treutlein J., Uhr M., van den Oord E.J., Van Grootheest G., Volzke H., Weilburg J.B., Willemsen G., Zitman F.G., Neale B., Daly M., Levinson D.F., Sullivan P.F. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 2013, 18:497-511.
98. Malkesman O., Austin D.R., Tragon T., Wang G., Rompala G., Hamidi A.B., Cui Z., Young W.S., Nakazawa K., Zarate C.A., Manji H.K., Chen G. Acute d-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 2012, 15:1135-1148.
99. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat. Med. 2001, 7:541-547.
100. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
101. McEwen B.S., Gianaros P.J. Stress- and allostasis-induced brain plasticity. Annu. Rev. Med. 2011, 62:431-445.
102. McGuffin P., Katz R., Watkins S., Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch. Gen. Psychiatry 1996, 53:129-136.
103. Meewisse M.L., Reitsma J.B., de Vries G.J., Gersons B.P., Olff M. Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis. Br. J. Psychiatry 2007, 191:387-392.
104. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 2006, 21:227-231.
105. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 2003, 28:720-725.
106. Miller L., Bansal R., Wickramaratne P., Hao X., Tenke C.E., Weissman M.M., Peterson B.S. Neuroanatomical correlates of religiosity and spirituality: a study in adults at high and low familial risk for depression. JAMA Psychiatry 2014, 71:128-135.
107. Modell S., Ising M., Holsboer F., Lauer C.J. The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol. Psychiatry 2005, 58:694-699.
108. Muhleisen T.W., Leber M., Schulze T.G., Strohmaier J., Degenhardt F., Treutlein J., Mattheisen M., Forstner A.J., Schumacher J., Breuer R., Meier S., Herms S., Hoffmann P., Lacour A., Witt S.H., Reif A., Muller-Myhsok B., Lucae S., Maier W., Schwarz M., Vedder H., Kammerer-Ciernioch J., Pfennig A., Bauer M., Hautzinger M., Moebus S., Priebe L., Czerski P.M., Hauser J., Lissowska J., Szeszenia-Dabrowska N., Brennan P., McKay J.D., Wright A., Mitchell P.B., Fullerton J.M., Schofield P.R., Montgomery G.W., Medland S.E., Gordon S.D., Martin N.G., Krasnow V., Chuchalin A., Babadjanova G., Pantelejeva G., Abramova L.I., Tiganov A.S., Polonikov A., Khusnutdinova E., Alda M., Grof P., Rouleau G.A., Turecki G., Laprise C., Rivas F., Mayoral F., Kogevinas M., Grigoroiu-Serbanescu M., Propping P., Becker T., Rietschel M., Nothen M.M., Cichon S. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat. Commun. 2014, 5:3339.
109. Musselman D.L., Nemeroff C.B. Depression and endocrine disorders: focus on the thyroid and adrenal system. Br. J. Psychiatry Suppl. 1996, 123-128.
110. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
111. Neumeister A., Nugent A.C., Waldeck T., Geraci M., Schwarz M., Bonne O., Bain E.E., Luckenbaugh D.A., Herscovitch P., Charney D.S., Drevets W.C. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch. Gen. Psychiatry 2004, 61:765-773.
112. Norbury R., Taylor M.J., Selvaraj S., Murphy S.E., Harmer C.J., Cowen P.J. Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology (Berl.) 2009, 206:197-204.
113. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 2006, 67(Suppl. 6):3-8.
114. Ota K.T., Liu R.J., Voleti B., Maldonado-Aviles J.G., Duric V., Iwata M., Dutheil S., Duman C., Boikess S., Lewis D.A., Stockmeier C.A., DiLeone R.J., Rex C., Aghajanian G.K., Duman R.S. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat. Med. 2014, 20:531-535.
115. Pankevich D.E., Altevogt B.M., Dunlop J., Gage F.H., Hyman S.E. Improving and accelerating drug development for nervous system disorders. Neuron 2014, 84:546-553.
116. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
117. Pieper A.A., Xie S., Capota E., Estill S.J., Zhong J., Long J.M., Becker G.L., Huntington P., Goldman S.E., Shen C.H., Capota M., Britt J.K., Kotti T., Ure K., Brat D.J., Williams N.S., MacMillan K.S., Naidoo J., Melito L., Hsieh J., De Brabander J., Ready J.M., McKnight S.L. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010, 142:39-51.
118. Pinhasov A., Crooke J., Rosenthal D., Brenneman D., Malatynska E. Reduction of submissive behavior model for antidepressant drug activity testing: study using a video-tracking system. Behav. Pharmacol. 2005, 16:657-664.
119. Pizzagalli D.A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011, 36:183-206.
120. Player M.J., Taylor J.L., Weickert C.S., Alonzo A., Sachdev P., Martin D., Mitchell P.B., Loo C.K. Neuroplasticity in depressed individuals compared with healthy controls. Neuropsychopharmacology 2013, 38:2101-2108.
121. Politis M., Niccolini F. Serotonin in Parkinson's disease. Behav. Brain Res. 2015, 277C:136-145.
122. Preskorn S., Macaluso M., Mehra D.O., Zammit G., Moskal J.R., Burch R.M., Group G.-C.S. Randomized proof of concept trial of GLYX-13, an N-methyl-d-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J. Psychiatr. Pract. 2015, 21:140-149.
123. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101 606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008, 28:631-637.
124. Quiroz J.A., Machado-Vieira R., Zarate C.A., Manji H.K. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010, 62:50-60.
125. Quitkin F.M., Stewart J.W., McGrath P.J., Tricamo E., Rabkin J.G., Ocepek-Welikson K., Nunes E., Harrison W., Klein D.F. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br. J. Psychiatry Suppl. 1993, 30-34.
126. Raison C.L., Miller A.H. Is depression an inflammatory disorder?. Curr. Psychiatry Rep. 2011, 13:467-475.
127. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
128. Risch N., Herrell R., Lehner T., Liang K.Y., Eaves L., Hoh J., Griem A., Kovacs M., Ott J., Merikangas K.R. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009, 301:2462-2471.
129. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
130. Russo S.J., Nestler E.J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 2013, 14:609-625.
131. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A., Manji H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 2009, 65:289-295.
132. Sanacora G., Rothman D.L., Mason G., Krystal J.H. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann. N.Y. Acad. Sci. 2003, 1003:292-308.
133. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
134. Schloesser R.J., Orvoen S., Jimenez D.V., Hardy N.F., Maynard K.R., Sukumar M., Manji H.K., Gardier A.M., David D.J., Martinowich K. Antidepressant-like effects of electroconvulsive seizures require adult neurogenesis in a neuroendocrine model of depression. Brain Stimul. 2015, 8:862-867.
135. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
136. Shaffer C.L., Hurst R.S., Scialis R.J., Osgood S.M., Bryce D.K., Hoffmann W.E., Lazzaro J.T., Hanks A.N., Lotarski S., Weber M.L., Liu J., Menniti F.S., Schmidt C.J., Hajos M. Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J. Pharmacol. Exp. Ther. 2013, 347:212-224.
137. Son H., Banasr M., Choi M., Chae S.Y., Licznerski P., Lee B., Voleti B., Li N., Lepack A., Fournier N.M., Lee K.R., Lee I.Y., Kim J., Kim J.H., Kim Y.H., Jung S.J., Duman R.S. Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11378-11383.
138. Steiger A., Kimura M. Wake and sleep EEG provide biomarkers in depression. J. Psychiatr. Res. 2010, 44:242-252.
139. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 2000, 157:1552-1562.
140. Tolosa E., Gaig C., Santamaria J., Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009, 72:S12-S20.
141. Treadway M.T., Zald D.H. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci. Biobehav. Rev. 2011, 35:537-555.
142. Trivedi M.H., Greer T.L., Church T.S., Carmody T.J., Grannemann B.D., Galper D.I., Dunn A.L., Earnest C.P., Sunderajan P., Henley S.S., Blair S.N. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J. Clin. Psychiatry 2011, 72:677-684.
143. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., Team S.D.S. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
144. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., Kim S.Y., Adhikari A., Thompson K.R., Andalman A.S., Gunaydin L.A., Witten I.B., Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
145. Urban D.J., Roth B.L. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 2014, 55:399-417.
146. Urry H.L., van Reekum C.M., Johnstone T., Kalin N.H., Thurow M.E., Schaefer H.S., Jackson C.A., Frye C.J., Greischar L.L., Alexander A.L., Davidson R.J. Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults. J. Neurosci. 2006, 26:4415-4425.
147. Valentine A.D., Meyers C.A., Kling M.A., Richelson E., Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin. Oncol. 1998, 25:39-47.
148. Victor T.A., Furey M.L., Fromm S.J., Ohman A., Drevets W.C. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch. Gen. Psychiatry 2010, 67:1128-1138.
149. Voleti B., Navarria A., Liu R.J., Banasr M., Li N., Terwilliger R., Sanacora G., Eid T., Aghajanian G., Duman R.S. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 2013, 74:742-749.
150. Vreeburg S.A., Hoogendijk W.J., van Pelt J., Derijk R.H., Verhagen J.C., van Dyck R., Smit J.H., Zitman F.G., Penninx B.W. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 2009, 66:617-626.
151. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., Kelley K.W., Dantzer R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
152. Waugh C.E., Muhtadie L., Thompson R.J., Joormann J., Gotlib I.H. Affective and physiological responses to stress in girls at elevated risk for depression. Dev. Psychopathol. 2012, 24:661-675.
153. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
154. Wilde A., Chan H.N., Rahman B., Meiser B., Mitchell P.B., Schofield P.R., Green M.J. A meta-analysis of the risk of major affective disorder in relatives of individuals affected by major depressive disorder or bipolar disorder. J. Affect. Disord. 2014, 158:37-47.
155. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl.) 1987, 93:358-364.
156. Witkin J.M., Overshiner C., Li X., Catlow J.T., Wishart G.N., Schober D.A., Heinz B.A., Nikolayev A., Tolstikov V.V., Anderson W.H., Higgs R.E., Kuo M.S., Felder C.C. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J. Pharmacol. Exp. Ther. 2014, 351:448-456.
157. Wu J.C., Buchsbaum M., Bunney W.E. Clinical neurochemical implications of sleep deprivation's effects on the anterior cingulate of depressed responders. Neuropsychopharmacology 2001, 25:S74-S78.
158. Wulff K., Gatti S., Wettstein J.G., Foster R.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 2010, 11:589-599.
159. Young E.A., Abelson J.L., Cameron O.G. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol. Psychiatry 2004, 56:113-120.
160. Young K.D., Bellgowan P.S., Bodurka J., Drevets W.C. Neurophysiological correlates of autobiographical memory deficits in currently and formerly depressed subjects. Psychol. Med. 2014, 44:2951-2963.
161. Young S.N., Smith S.E., Pihl R.O., Ervin F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl.) 1985, 87:173-177.
162. Zarate C., Duman R.S., Liu G., Sartori S., Quiroz J., Murck H. New paradigms for treatment-resistant depression. Ann. N.Y. Acad. Sci. 2013, 1292:21-31.
163. Zorrilla E.P., Koob G.F. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov. Today 2010, 15:371-383.